TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06218784
Drug: Placebo Capsule (Part 3)
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: b.i.d for 14 days
Study: NCT04880889
Drug: Reference Pantogar
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT04880889
Drug: BL3000 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule 500 mg
Study: NCT04880889
Drug: Pantogar - Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT06092957
Drug: Full course of PD-1/PD-L1 blockades
Approvals — FDA: no, EMA: no, PMDA: no
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Study: NCT00000778
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05157763
Drug: EscharEx 5% (EX-02 formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
Study: NCT04817800
Drug: 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be nasaly administered
Study: NCT06372483
Drug: VMX-C001
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Study: NCT06372483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMX-C001 matched placebo
Study: NCT04993768
Drug: TPN-101, 100 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
Study: NCT04993768
Drug: TPN-101, 200 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
Study: NCT04993768
Drug: TPN-101, 400 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
Study: NCT04993768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
Study: NCT06059001
Drug: OMO-103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
Study: NCT05738291
Drug: Placebo matching BI 1839100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1839100
Study: NCT05738291
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin
Study: NCT05432960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (0.9% Sodium Chloride solution)
Study: NCT05712889
Drug: VIP236 (Q3W)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.
Study: NCT05712889
Drug: VIP236 (Q2W)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.
Study: NCT05514444
Drug: 89Zr-MK-4464
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89ZR-MK-4464 administered as an IV infusion on C1D1.
Study: NCT04650841
Drug: Placebo Cream with Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
Study: NCT04650841
Drug: Control Cream with Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be informed that the spray is saline.
Study: NCT05810116
Drug: Levagen+
Normalized name: Levafen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
Study: NCT05990543
Drug: Nelmastobart and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.~Capecitabine is administered orally for two weeks followed by a one-week rest period
Study: NCT00240773
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 grams daily for six months
Study: NCT00240773
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750 mg daily for 12 months
Study: NCT00240773
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 grams daily for 12 months
Study: NCT00240773
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750 mg daily for six months
Study: NCT06359535
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is an economic study and does not interfere with patients' medical treatment.
Study: NCT06359535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05799157
Drug: Vehicle Patch
Normalized name: EXYDERM Transdermal Vehicle Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo microneedle patch containing no active drug (i.e., placebo)
Study: NCT06345703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS-136 matching placebo
Study: NCT06195111
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
Study: NCT04262427
Drug: Cyclophosphamide 50mg
Normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cytotoxic chemotherapy
Study: NCT05516407
Drug: FEN164
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Study: NCT06220266
Drug: Phytoestrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: consume 1 capsule twice a day for 2 months which one capsule composed of dry weight 50 mg of Pueraria Mirifica 1or Pueraria Mirifica 2 or Pueraria Mirifica 3
Study: NCT05417386
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
Study: NCT05417386
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study: NCT05417386
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken Orally as part of Chemoradiation
Study: NCT06500689
Drug: Allisartan Isoproxil/Sustained-Release Indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide.
Study: NCT06312670
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist/antagonist or orchiectomy
Study: NCT05741710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
Study: NCT05759364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05704049
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)
Study: NCT06168799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
Study: NCT04857034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05719389
Drug: CT-P13
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 is a biosimilar of infliximab approved by EMA since 2015, and it is administered intravenously (i.v.) at a standard dose of 5 mg/kg at week 0, 2, 6 and then every 8 weeks, although the scheduled maintenance regimen can be optimized by administering the drug every 4-6 weeks or increasing the dose up to 10 mg/kg2.The safety profile of CT-P13 SC was comparable to that of CT-P13 i.v.; There were also fewer patients with positive anti-drug antibodies with CT-P13 SC than with CT-P13 i.v.3 At the moment, no data are available on the effectiveness, safety and immunogenicity in a real-world population of patients who have been switched from i.v. to s.c. infliximab.
Study: NCT05507216
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily in the morning with food
Study: NCT05507216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily in the morning with food
Study: NCT06053411
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg capsule
Study: NCT05521282
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
Study: NCT06107686
Drug: YL202 should be intravenously infused
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each patient, YL202 should be intravenously infused over 60±10 min.
Study: NCT06430411
Drug: Androgen deprivation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as part of multimodal treatment for oligometastatic prostate cancer
Study: NCT05020119
Drug: Neoantigen-expanded cell therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of personalized neoantigen-expanded T (CIK) cells
Study: NCT04641975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/ Oral Suspension
Study: NCT05685407
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
Study: NCT06440746
Drug: Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
Study: NCT06440746
Drug: SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.
Study: NCT05304962
Drug: RGT-419B
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT05313256
Drug: Lidocaine epinephrine buffered with sodium bicarbonate
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
Study: NCT05313256
Drug: Lidocaine epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
Study: NCT04344860
Drug: Recombinant Von Willebrand factor
Normalized name: VON WILLEBRAND FACTOR,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
Study: NCT04213274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
Study: NCT05823883
Drug: DW6014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition
Study: NCT04593329
Drug: TIRADENTES ASSOCIATION
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiradentes association tablet
Study: NCT05734807
Drug: Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive NrtIs therapy for 24 weeks.
Study: NCT05734807
Drug: HH-003, NrtIs and PEG-IFN-α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
Study: NCT05984992
Drug: SRN-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized
Study: NCT05984992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride(Normal saline)
Study: NCT04560309
Drug: L-alanyl-L-glutamine dipeptide
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
Study: NCT04560309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
Study: NCT05814939
Drug: VC005 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 groups repeat administration for 12 weeks
Study: NCT05979818
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Study: NCT05814939
Drug: VC005 Tablets Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 placebo groups repeat administration for 12 weeks
Study: NCT05675293
Drug: ORAL ANTIBIOTIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Antibiotic
Study: NCT06081465
Drug: VG290131
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug and matching placebo will be administered orally.
Study: NCT05108974
Drug: Choline Bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered drink mix for daily consumption
Study: NCT05284747
Drug: Routine Lipid Management
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
Study: NCT05249348
Drug: PC14586
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
Study: NCT06048705
Drug: GSK3901961
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3901961 was administered.
Study: NCT06048705
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered as lymphodepleting chemotherapy.
Study: NCT05478707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo
Study: NCT06465602
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.
Study: NCT06465602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
Study: NCT06125327
Drug: SC1011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
Study: NCT06125327
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
Study: NCT05240976
Drug: NMDAE plus AIFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
Study: NCT05240976
Drug: NMDAE plus Placebo Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of an NMDA enhancer plus placebo as a comparator
Study: NCT05280314
Drug: IO102-IO103
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
Study: NCT04654052
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-intervention
Study: NCT05788328
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin as oral tablet
Study: NCT05527314
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
Study: NCT05527314
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Study: NCT05624957
Drug: Lidocaine epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
Study: NCT04632381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose injection, USP
Study: NCT05092503
Drug: JINZHEN Granules for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: JINZHEN granules will be dissolved in drinking water and administered orally.
Study: NCT05092503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules will be dissolved in drinking water and administered orally.
Study: NCT06532344
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05257213
Drug: Heparin solution
Normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 ml saline solution containing 5000 IU heparin.
Study: NCT05257213
Drug: Anti-adhesion barrier gel
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
Study: NCT04990310
Drug: [14C]-CORT113176
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
Study: NCT06223009
Drug: cNP8
Approvals — FDA: no, EMA: no, PMDA: no
Description: cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
Study: NCT02544815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills
Study: NCT05883449
Drug: AB-101
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell therapy, intravenous infusion
Study: NCT05883449
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy, intravenous infusion
Study: NCT05909709
Drug: Alocyte medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose containing 0.6 - 3.0 x 10\^11 particles and 9-30x10\^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used.
Study: NCT05395494
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral placebo during the TMS treatments (20 days).